Intelligent Bio Solutions Inc. (INBS), a medical technology company, today, announced that it is on track to make an FDA 510(k) submission for its Intelligent Fingerprinting Drug Screening System this quarter.
The Intelligent Fingerprinting Drug Screening System is designed to detect recent use of substances commonly encountered in the workplace, such as opioids, cocaine, methamphetamine, and cannabis, by analyzing sweat from fingerprints. This non-invasive, portable system serves as a deterrent against drug abuse and encourages employees to adhere to health and safety policies.
In a clinical study, the Intelligent Fingerprinting Drug Screening System demonstrated 82.2% sensitivity, 100% specificity, and 94.1% accuracy, the company noted.
If all goes well as planned, the company expects to commercialize the Intelligent Fingerprinting Drug Screening System in the U.S. by 2025.
The Intelligent Fingerprinting Drug Screening System is commercially available in certain countries outside of the United States including the UK, South America, Australia, and New Zealand.
INBS is currently trading at $1.53, up 1.32%.
For comments and feedback contact: editorial@rttnews.com
Business News
April 24, 2026 15:15 ET Economics news flow was relatively light this week even as the conflict in the Middle East continued, raising concerns for policymakers. In the U.S., spending data, initial jobless claims and pending home sales were the highlights. Business confidence in the biggest euro area economy was in focus in Europe. Inflation data from Japan gained attention in Asia.